Cytosorbents Corp 8-K

What Happened

• CytoSorbents Corporation (CTSO) filed an 8-K reporting that on June 29, 2026 it received a notice from the Nasdaq Listing Qualifications Department saying the company is not in compliance with Nasdaq Listing Rule 5550(b)(2) because its Market Value of Listed Securities (MVLS) is below the $35 million minimum required for the Nasdaq Capital Market. Nasdaq gave the company 180 calendar days — until December 28, 2026 — to regain compliance.

Key Details

• Nasdaq requirement cited: MVLS must be at least $35,000,000.
• Compliance deadline: 180 days from notice, ending December 28, 2026; compliance requires MVLS ≥ $35M for at least 10 consecutive business days (subject to staff discretion).
• Current status: The notice does not result in immediate delisting; the company is evaluating actions and will monitor its market value.
• Alternative compliance option mentioned: increase stockholders’ equity to at least $2.5 million; if noncompliant after the period, the company would receive a delisting notice and could appeal.

Why It Matters

• For investors, this is a formal warning that CTSO faces a potential delisting risk if its market capitalization does not recover to Nasdaq’s threshold within the 180-day cure period. Delisting could reduce liquidity and limit where the stock trades. The company has options (market cap improvement, boosting stockholders’ equity, or appeal), but the filing cautions there is no assurance it will maintain its Nasdaq listing.